Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Drug brain

Pardridge WM, Log(BB). PS products and in silico models of drug brain penetration. Drug Discov Today 2004 9 392-3. [Pg.510]

Drug Brain Monoaminergic Neurons Showing Neurotoxic Damage Neurotoxicity Occurring in Humans... [Pg.349]

Barbeau H Rossignol S. (1991). Initiation and modulation of the locomotor pattern in the adult chronic spinal cat by noradrenergic, serotonergic and dopaminergic drugs. Brain Res. 546(2), 250-60. [Pg.207]

Sakurai Y, Takano Y, Kohjimoto Y, Honda K, Kamiya HO. (1982). Enhancement of [3H]dopamine release and its [3H]metabolites in rat striatum by nicotinic drugs. Brain Res. 242(1) 99-106. Schechter MD. (1990). Rats become acutely tolerant to cathine after amphetamine or cathinone administration. Psychopharmacology (Berlin). 101(1) 126-31. [Pg.462]

Quirarte G, Galvez R, Roozendaal B, McGaugh JL. 1998. Norepinephrine release in the amygdala in response to footshock and opiod peptidergic drugs. Brain Res 808(2) 134-140. [Pg.252]

Uhlen S, Undblom J, Johnson A, Wikberg JE (1997) Autoradiographic studies of central a2A- and a2c-adrenoceptors in the rat using [ H]MK912 and subtype-selective drugs. Brain Res 770 261-266... [Pg.185]

Howard, Pierce J. The Owner s Manual for the Brain Everyday Applications from Mind-Brain Research, 3rd ed. Austin, Tex. Bard Press, 2006. With scientific research as its starting point, this book discusses how the present state of knowledge in brain science can have a practical impact on human lives. A wide variety of topics are discussed, including brain chemistry, the effects of drugs, brain disorders, learning and memory, and much else. [Pg.102]

Linden, David. The Accidental Mind How brain evolution has given us love, memory, dreams, and God. Cambridge Harvard University Press, 2007. Meyer, Jerrold S., Linda F. Quenzer. Psychopharmacology Drugs, Brain and Behavior. Sinauer, 2005. [Pg.169]

Olivier, J.C., et al. 1999. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 16 1836. [Pg.612]

Di Chiara G, Acquas E, Carboni E (1991) In P. Willner and J. Scheel-Kruger (eds) Role of mesolimbic dopamine in the motivational effects of drug brain dialysis and place preference studies. In The mesolimbic dopamine system from motivation to action. John Wiley and Sons Publ., Chichester, UK... [Pg.390]

Collection and Treatment of Brain Samples Brains were obtained form animals, which were sacrificed 3 h post oral dosing of the drug. Brains of untreated (control) animals were used in order to obtain the blank brain homogenates for calibration standard and quality control samples (control animals received the pure vehicle, 0.2 % w/v agarose gel). [Pg.623]

Ragsdale DS, Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res Rev 1998 26 16-28. [Pg.77]

Ferger, D. and Krieglstein, J., Determination of intracellular Ca concentration can be a useful tool to predict neuronal damage and neuroprotection properties of drugs, Brain Res., 932, 87, 1996. [Pg.325]

Steingart, R. A., Barg, J Maslaton, J., Nesher, M, and Yanai. J. (1998), Pre- and postsynaptic alterations in the scptohippocani-pal cholinergic innervations after prenatal exposure to drugs Brain Res. Bull. 46, 203-209. [Pg.313]

Westerink BHC, Dijkstra D, et al. Dopaminergic pro-drugs brain concentrations and neurochemical effects of 5,6- and 6,7-ADTN after administration as dibenzoyl esters. Eur J Pharmacol 1980 61 7-15. [Pg.1056]

Figure 10.10 Top antipsychotics haloperidol and risperidone. Bottom H3 receptor antagonists/inverse agonists ciproxifan and ABT-239 (Zhang, M., et ah Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res. 2005, 1045, 142-149). Figure 10.10 Top antipsychotics haloperidol and risperidone. Bottom H3 receptor antagonists/inverse agonists ciproxifan and ABT-239 (Zhang, M., et ah Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Res. 2005, 1045, 142-149).
M. Fink, Drugs Brain, 149 (1969). Edited by P. Black, Johns Hopkins Press, Baltimore, Md. [Pg.30]


See other pages where Drug brain is mentioned: [Pg.107]    [Pg.165]    [Pg.166]    [Pg.198]    [Pg.23]    [Pg.31]    [Pg.287]    [Pg.31]    [Pg.43]    [Pg.689]    [Pg.383]    [Pg.416]    [Pg.4]    [Pg.275]   
See also in sourсe #XX -- [ Pg.168 ]




SEARCH



Blood brain barrier drug efflux transport systems role

Blood brain barrier drug modification

Blood brain barrier restricting drug efflux

Blood brain barrier vector-mediated drug delivery

Blood-brain barrier drug delivery

Blood-brain barrier drug efflux system

Blood-brain barrier nasal drug delivery

Blood-brain barrier, drug distribution

Brain drug delivery

Brain drug passage into

Brain drug targeting

Brain penetration of drugs

Brain targeted drug delivery

Brain-function enhancing drugs

Central nervous system drugs blood-brain barrier

Drug Delivery to the Brain

Drugs and the Brain

Drugs blood-brain barrier

Neuroleptic drugs Brain damage

Psychiatric Drugs: Hazards to the Brain

Site-specific drug delivery brain targeting

Types of Nanocarriers for Drug Delivery to the Brain

Vector-mediated drug delivery, blood-brain

© 2024 chempedia.info